The tweet was deleted by the author.
But we saved everything 🙂.
Neurogene Inc. released its full year 2025 financial results today, providing investors with insights into the company’s performance and strategic direction.
Alongside the financial disclosures, Neurogene Inc. detailed recent advancements in its NGN-401 program, highlighting efforts to progress its pipeline. The update emphasizes the company’s commitment to continued research and development in rare genetic diseases. Full details are available in the linked company report.
Earlier this year, Neurogene Inc. secured FDA Breakthrough Therapy Designation for NGN-401, a gene therapy candidate for Rett syndrome. The designation recognizes the program’s potential for treating rare genetic diseases. Neurogene has continued to prioritize the development of NGN-401 within its pipeline.